Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
21.49 (USD) • At close September 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Arrowhead Pharmaceuticals, Inc. |
Symbool | ARWR |
Munteenheid | USD |
Prijs | 21.49 |
Beurswaarde | 2,671,529,350 |
Dividendpercentage | 0% |
52-weken bereik | 20.14 - 39.83 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Christopher R. Anzalone Ph.D. |
Website | https://arrowheadpharma.com |
An error occurred while fetching data.
Over Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)